@entity28807 stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for @entity157 ( @entity157 ). Thirty @entity157 @entity1 underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% @entity39 of all @entity5 . Partial response (PR) was defined as > or = 50% reduction and/or > or = 50% @entity39 . We regarded the @entity4831 accumulation in @entity5 as being @entity39 . CR and PR were observed in 8 @entity1 (27%) and 4 @entity1 (13%), respectively, and the overall response rate (CR + PR/all @entity1 ) was 40% (12/30). Of 12 patients whose serum @entity160 levels had been more than 200 ng/ml before treatment, 5 @entity1 (42%) showed more than 50% reduction in this level within 1 month after treatment. @entity137 was quite acceptable, although grade 4 @entity137 (WHO) was observed as @entity409 in 1 @entity1 . Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in @entity1 with @entity157 .

Transarterial chemotherapy with XXXX stimalamer for @entity157 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrotic', 'necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver dysfunction'] @entity28807 :: ('MESH:D009353', 'Chemical') :: ['Zinostatin'] @entity4831 :: ('MESH:D004998', 'Chemical') :: ['lipiodol'] @entity160 :: ('174', 'Gene') :: ['alpha-fetoprotein'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']
@entity28807 :: (MESH:D009353,Chemical) :: ['zinostatin']
